Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel.

PubWeight™: 0.86‹?›

🔗 View Article (PMC 2801158)

Published in Coron Artery Dis on May 01, 2009


Julie H Oestreich1, John Holt, Steven P Dunn, Susan S Smyth, Charles L Campbell, Richard Charnigo, Wendell S Akers, Steven R Steinhubl

Author Affiliations

1: Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536-0293, USA.

Associated clinical trials:

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome (PLATO) | NCT00391872

GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety (GRAVITAS) | NCT00645918

Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS (CURRENT/OASIS7) | NCT00335452

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. (Platform) | NCT00385138

Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel (MATTIS-D) | NCT01643031

Articles cited by this

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med (2001) 20.20

Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 11.06

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation (2004) 4.56

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation (2003) 3.92

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol (2008) 3.65

Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation (2005) 3.25

ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation (2006) 2.98

Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation (2001) 2.73

Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol (2005) 2.59

High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost (2005) 2.52

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol (2007) 2.08

Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation (2005) 2.05

Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost (2003) 1.97

Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation (2005) 1.89

Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol (2005) 1.81

A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J (2007) 1.71

Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation (2007) 1.61

Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol (2006) 1.51

Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart (2005) 1.45

The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost (2007) 1.11

Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation (2004) 1.07

Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol (2006) 1.02

Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. Semin Thromb Hemost (1999) 0.97

Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets (2002) 0.96

How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Thromb Haemost (2008) 0.96

Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res (2007) 0.93

Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets (2008) 0.92

Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol (2004) 0.87

Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. Am J Cardiol (2007) 0.86

Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Thromb Haemost (2008) 0.81

Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. J Cardiovasc Pharmacol Ther (2007) 0.81

Optimizing platelet P2Y12 inhibition for patients undergoing PCI. Cardiovasc Drug Rev (2007) 0.79

Articles by these authors

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07

Sudden death in young adults: a 25-year review of autopsies in military recruits. Ann Intern Med (2004) 4.18

Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68

Increased mortality among patients taking digoxin--analysis from the AFFIRM study. Eur Heart J (2012) 3.52

Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation (2003) 3.38

Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA (2007) 3.28

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA (2008) 3.09

Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol (2005) 3.05

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA (2004) 2.89

Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol (2005) 2.59

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56

Rap1b is required for normal platelet function and hemostasis in mice. J Clin Invest (2005) 2.46

Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J (2004) 2.42

An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J (2007) 2.31

Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation. Blood (2011) 2.27

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation (2010) 2.27

The effect of donor age on corneal transplantation outcome results of the cornea donor study. Ophthalmology (2008) 2.19

Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation (2008) 2.05

Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J Am Coll Cardiol (2004) 2.04

ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice. Am J Physiol Heart Circ Physiol (2009) 2.01

Investigation of clusters of giardiasis using GIS and a spatial scan statistic. Int J Health Geogr (2004) 1.98

Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol (2007) 1.97

Donor age and corneal endothelial cell loss 5 years after successful corneal transplantation. Specular microscopy ancillary study results. Ophthalmology (2008) 1.94

Rapid dilation of the abdominal aorta during infusion of angiotensin II detected by noninvasive high-frequency ultrasonography. J Vasc Surg (2006) 1.91

Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol (2011) 1.81

Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A (2010) 1.80

Adipocyte-specific deficiency of angiotensinogen decreases plasma angiotensinogen concentration and systolic blood pressure in mice. Am J Physiol Regul Integr Comp Physiol (2011) 1.79

Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J Biol Chem (2009) 1.78

Endothelial cell-specific deficiency of Ang II type 1a receptors attenuates Ang II-induced ascending aortic aneurysms in LDL receptor-/- mice. Circ Res (2011) 1.78

Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation (2009) 1.77

Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Circulation (2007) 1.67

Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol (2007) 1.66

Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol (2008) 1.62

Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization. J Invasive Cardiol (2006) 1.61

Obesity promotes inflammation in periaortic adipose tissue and angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol (2009) 1.59

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. JACC Cardiovasc Interv (2009) 1.56

Cardiac response to pressure overload in 129S1/SvImJ and C57BL/6J mice: temporal- and background-dependent development of concentric left ventricular hypertrophy. Am J Physiol Heart Circ Physiol (2006) 1.52

The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. Eur Heart J (2009) 1.49

Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J (2011) 1.47

A brief, clinic-based, safer sex intervention for heterosexual African American men newly diagnosed with an STD: a randomized controlled trial. Am J Public Health (2009) 1.46

Early coronary revascularization diminishes the risk of ischemic stroke with acute myocardial infarction. Stroke (2006) 1.44

Prolonged infusion of angiotensin II in apoE(-/-) mice promotes macrophage recruitment with continued expansion of abdominal aortic aneurysm. Am J Pathol (2011) 1.43

Is there an association between external cardioversions and long-term mortality and morbidity? Insights from the Atrial Fibrillation Follow-up Investigation of Rhythm Management study. Circ Arrhythm Electrophysiol (2011) 1.42

Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass. J Thromb Thrombolysis (2012) 1.41

Variable response to antiplatelet therapy: what does it mean to clinicians? Cleve Clin J Med (2007) 1.40

Recipient risk factors for graft failure in the cornea donor study. Ophthalmology (2009) 1.40

Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study). Am J Cardiol (2002) 1.37

Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am J Cardiol (2008) 1.36

First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation (2006) 1.35

Periostin mediates vascular smooth muscle cell migration through the integrins alphavbeta3 and alphavbeta5 and focal adhesion kinase (FAK) pathway. Atherosclerosis (2009) 1.33

Continuous versus intermittent infusion of furosemide in acute decompensated heart failure. J Card Fail (2010) 1.30

Geographical and temporal distribution of human giardiasis in Ontario, Canada. Int J Health Geogr (2003) 1.30

Therapeutic potential of autotaxin/lysophospholipase d inhibitors. Curr Drug Targets (2008) 1.27

Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv (2011) 1.26

Importance of direct patient care in advanced pharmacy practice experiences. Pharmacotherapy (2012) 1.26

Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling. Arterioscler Thromb Vasc Biol (2009) 1.23

The effect of donor age on penetrating keratoplasty for endothelial disease: graft survival after 10 years in the Cornea Donor Study. Ophthalmology (2013) 1.23

Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. Mol Endocrinol (2012) 1.21

Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice. Hypertension (2012) 1.21

Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ Res (2008) 1.20

Characterization of a model to independently study regression of ventricular hypertrophy. J Surg Res (2007) 1.19

Src family kinases mediate neutrophil adhesion to adherent platelets. Blood (2006) 1.16

Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation. Am J Respir Crit Care Med (2013) 1.15

Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation (2008) 1.14

Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested. Circulation (2003) 1.14

New data, same story? Revisiting studies on the relationship of local public health systems characteristics to public health performance. J Public Health Manag Pract (2010) 1.13

The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema. Ann Pharmacother (2011) 1.12

Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells. J Biol Chem (2011) 1.11

Food insecurity and maternal depression in rural, low-income families: a longitudinal investigation. Public Health Nutr (2008) 1.11

Integrin αIIbβ3: from discovery to efficacious therapeutic target. Circ Res (2013) 1.11

G-protein-coupled receptors as signaling targets for antiplatelet therapy. Arterioscler Thromb Vasc Biol (2008) 1.10

The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J (2008) 1.10

Depression and poverty among rural women: a relationship of social causation or social selection? J Rural Health (2008) 1.10

Plasma levels of sphingosine 1-phosphate are strongly correlated with haematocrit, but variably restored by red blood cell transfusions. Clin Sci (Lond) (2011) 1.10

The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol (2006) 1.09

Mechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice. J Lipid Res (2013) 1.09

Mice with targeted inactivation of ppap2b in endothelial and hematopoietic cells display enhanced vascular inflammation and permeability. Arterioscler Thromb Vasc Biol (2014) 1.08

Transient exposure of neonatal female mice to testosterone abrogates the sexual dimorphism of abdominal aortic aneurysms. Circ Res (2012) 1.07

The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol (2009) 1.07

A phosphatidic acid binding/nuclear localization motif determines lipin1 function in lipid metabolism and adipogenesis. Mol Biol Cell (2010) 1.07

Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J (2008) 1.07

Src-family kinases mediate an outside-in signal necessary for beta2 integrins to achieve full activation and sustain firm adhesion of polymorphonuclear leucocytes tethered on E-selectin. Biochem J (2006) 1.05

Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nat Commun (2013) 1.05

Lipid phosphate phosphatase 3 negatively regulates smooth muscle cell phenotypic modulation to limit intimal hyperplasia. Arterioscler Thromb Vasc Biol (2012) 1.04

Platelets as immune mediators: their role in host defense responses and sepsis. Thromb Res (2010) 1.04

CX3CR1 deficiency confers protection from intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol (2006) 1.04

Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid. J Lipid Res (2013) 1.03

Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res (2007) 1.03

Thrombosis and antithrombotic therapy in women. Arterioscler Thromb Vasc Biol (2009) 1.03

Individual heterogeneity in platelet response to lysophosphatidic acid: evidence for a novel inhibitory pathway. Arterioscler Thromb Vasc Biol (2008) 1.02

The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J (2012) 1.02

Distinct roles for Rap1b protein in platelet secretion and integrin αIIbβ3 outside-in signaling. J Biol Chem (2011) 1.01

Total lymphocyte deficiency attenuates AngII-induced atherosclerosis in males but not abdominal aortic aneurysms in apoE deficient mice. Atherosclerosis (2010) 1.01

Reproducibility of cine displacement encoding with stimulated echoes (DENSE) cardiovascular magnetic resonance for measuring left ventricular strains, torsion, and synchrony in mice. J Cardiovasc Magn Reson (2013) 1.00